Comparative Pharmacology
Head-to-head clinical analysis: BRISDELLE versus LEXAPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISDELLE versus LEXAPRO.
BRISDELLE vs LEXAPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
8 mg orally once daily, taken at bedtime.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
None Documented
None Documented
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant